Mildronate exerts acute anticonvulsant and antihypnotic effects

Behavioural Pharmacology

Volumn 21, Issue 5-6, 2010, Pages 548-555

  Zvejniece, Liga ^a   Svalbe, Baiba ^a,b   Makrecka, Marina ^a,c   Liepinsh, Edgars ^a   Kalvinsh, Ivars ^a   Dambrova, Maija ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b UNIVERSITY OF LATVIA   (Latvia)

^c RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

Anticonvulsant; cerebral blood flow; ethanol induced loss of righting reflex; mildronate; mouse; oxygen saturation; pentylenetetrazole; rat

Indexed keywords

ALCOHOL; BICUCULLINE; MILDRONATE; N(G) NITROARGININE; PENTETRAZOLE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYPNOSIS; IN VIVO STUDY; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; RAT; REFLEX; SLEEP TIME; TONIC SEIZURE;

ALCOHOLIC INTOXICATION; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; METHYLHYDRAZINES; MICE; MICE, INBRED ICR; NITRIC OXIDE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; SEIZURES; SLEEP;

EID: 77955981838     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833d5a59     Document Type: Article

References (40)

1. Augustyniak A, Skrzydlewska E (2009). L-Carnitine in the lipid and protein protection against ethanol-induced oxidative stress. Alcohol 43:217-223.
2. Binienda Z, Przybyla-Zawislak B, Virmani A, Schmued L (2005). L-carnitine and neuroprotection in the animal model of mitochondrial dysfunction. Ann N Y Acad Sci 1053:174-182.
3. Corda MG, Orlandi M, Lecca D, Carboni G, Frau V, Giorgi O (1991). Pentylenetetrazol-induced kindling in rats: effect of GABA function inhibitors. Pharmacol Biochem Behav 40:329-333.
4. Cremer CM, Palomero-Gallagher N, Bidmon HJ, Schleicher A, Speckmann EJ, Zilles K (2009). Pentylenetetrazole-induced seizures affect binding site densities for GABA, glutamate and adenosine receptors in the rat brain. Neuroscience 163:490-499.
5. Dambrova M, Liepinsh E, Kalvinsh I (2002). Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 12:275-279.
6. Dambrova M, Cirule H, Svalbe B, Zvejniece L, Pugovichs O, Zorenko T, et al. (2008). Effect of inhibiting carnitine biosynthesis on male rat sexual performance. Physiol Behav 95:341-347.
7. De Sarro GB, Donato Di PE, De SA, Vidal MJ (1991). Role of nitric oxide in the genesis of excitatory amino acid-induced seizures from the deep prepiriform cortex. Fundam Clin Pharmacol 5:503-511.
8. Draski LJ, Deitrich RA (1993). Initial effects of ethanol on the central nervous system. Pharmacological Effects of Ethanol on the Nervous System. Boca Raton: CRC Press; pp. 227-249.
9. Dziak LA, Golik VA (2003). Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head. Lik Sprava 5-6:98-101.
10. Dzintare M, Baumane L, Meirena D, Lauberte L, Kalvinsh I, Sjakste N (2002). Involvement of nitric oxide production in the mildronate mechanism of action. Pharmacology Reviews and Communications 12:163-170.
11. Fariello RG, Shug AL (1981). Competitive inhibition by 3-aminopropanesulfonic acid and gamma-aminobutyric acid of carnitine transport in rat brain slices. Biochem Pharmacol 30:1012-1013.
12. Foster DW (2004). The role of the carnitine system in human metabolism. Ann N Y Acad Sci 1033:1-16.
13. Golovacheva MO (2006). Neuroprotective treatment of patients with normal tension glaucoma. Georgian Med News 131:37-40.
14. Homayoun H, Khavandgar S, Namiranian K, Gaskari SA, Dehpour AR (2002). The role of nitric oxide in anticonvulsant and proconvulsant effects of morphine in mice. Epilepsy Res 48:33-41.
15. Jones LL, McDonald DA, Borum PR (2010). Acylcarnitines: role in brain. Prog Lipid Res 49:61-75.
16. Koudelova J, Mourek J, Drahota Z, Rauchova H (1994). Protective effect of carnitine on lipoperoxide formation in rat brain. Physiol Res 43:387-389.
17. Kuwajima M, Harashima H, Hayashi M, Ise S, Sei M, Lu K, et al. (1999). Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2- trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther 289:93-102.
18. Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M (2006). Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol 48:314-319.
19. Liepinsh E, Vilskersts R, Skapare E, Svalbe B, Kuka J, Cirule H, et al. (2008). Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci 83:613-619.
20. Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, et al. (2009a). Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. Br J Pharmacol 157:1549-1556.
21. Liepinsh E, Kuka J, Svalbe B, Vilskersts R, Skapare E, Cirule H, et al. (2009b). Effects of long-term mildronate treatment on cardiac and liver functions in rats. Basic Clin Pharmacol Toxicol 105:387-394.
22. Loscher W, Honack D, Fassbender CP, Nolting B (1991). The role of technical, biological and pharmacological factors in the laboratory evaluation of antic-onvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8:171-189.
23. Mandhane SN, Aavula K, Rajamannar T (2007). Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. Seizure 16:636-644.
24. Maresova D, Rauchova H, Jandova K, Valkounova I, Koudelova J, Trojan S (2001). Carnitine pretreatment can partially change the excitability of the immature nervous tissue. Physiol Res 50:439-442.
25. Matsuoka M, Igisu H (1992). Preservation of energy metabolites by carnitine in the mouse brain under ischemia. Brain Res 590:334-336.
26. Meldrum BS (1975). Epilepsy and gamma-aminobutyric acid-mediated inhibition. Int Rev Neurobiol 17:1-36.
27. Nidhi G, Balakrishnan S, Pandhi P (1999). Role of nitric oxide in electroshock and pentylenetetrazole seizure threshold in rats. Methods Find Exp Clin Pharmacol 21:609-612.
28. Psarropoulou C, Matsokis N, Angelatou F, Kostopoulos G (1994). Pentylenete-trazol-induced seizures decrease gamma-aminobutyric acid-mediated recurrent inhibition and enhance adenosine-mediated depression. Epilepsia 35:12-19.
29. Riazi K, Roshanpour M, Rafiei-Tabatabaei N, Homayoun H, Ebrahimi F, Dehpour AR (2006). The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway. Br J Pharmacol 147:935-943.
30. Sakvarelidze EP (2006). Change of concentration of L-carnitine in blood and other tissues in rats on a background of the alcohol intake and influence of mildronate on its level. Georgian Med News 137:94-96.
31. Simkhovich BZ, Shutenko ZV, Meirena DV, Khagi KB, Mezapuke RJ, Molodchina TN, et al. (1988). 3-(2,2,2-Trimethylhydrazinium)propionate (THP) a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 37:195-202.
32. Sizova EN, Tsirkin VI, Dvorianskii SA (2002). The role of endogenous modulators of chemoreactivity in the regulation of coronary blood flow. Ross Fiziol Zh Im I M Sechenova 88:856-864.
33. Sjakste N, Gutcaits A, Kalvinsh I (2005). Mildronate: an antiischemic drug for neurological indications. CNS Drug Rev 11:151-168.
34. Starr MS, Starr BS (1993). Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthesis inhibitor L-NAME. Pharmacol Biochem Behav 45:321-325.
35. Statsenko ME, Poletaeva LV, Turkina SV, Apukhtin AF, Dudchenko GP (2008). Mildronate effects on oxidant stress in type 2 diabetic patients with diabetic peripheral (sensomotor) neuropathy. Ter Arkh 80:27-30.
36. Szot P, Lester M, Laughlin ML, Palmiter RD, Liles LC, Weinshenker D (2004). The anticonvulsant and proconvulsant effects of alpha2-adrenoreceptor agonists are mediated by distinct populations of alpha2A-adrenoreceptors. Neuroscience 126:795-803.
37. Takada J, Ibayashi S, Nagao T, Ooboshi H, Kitazono T, Fujishima M (2001). Bradykinin mediates the acute effect of an angiotensin-converting enzyme inhibitor on cerebral autoregulation in rats. Stroke 32:1216-1219.
38. Tsuda M, Suzuki T, Misawa M (1997). Aggravation of DMCM-induced seizure by nitric oxide synthase inhibitors in mice. Life Sci 60:339-343.
39. Vinichuk SM (1991). The efficacy of the mildronate treatment of patients with ischemic stroke. Vrach Delo 7:77-79.
40. Yu Z, Iryo Y, Matsuoka M, Igisu H, Ikeda M (1997). Suppression of pentylenetetrazol-induced seizures by carnitine in mice. Naunyn Schmiedebergs Arch Pharmacol 355:545-549.